Skip to main content
Highnoon Laboratories Limited logo

Highnoon Laboratories Limited — Investor Relations & Filings

Ticker · HINOON ISIN · PK0070801011 PSX Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2026-05-15 Notice of Dividend Amou…
Country PK Pakistan
Listing PSX HINOON

About Highnoon Laboratories Limited

https://highnoon-labs.com/

Highnoon Laboratories Limited is a pharmaceutical company focused on the development, production, marketing, and distribution of modern, high-quality, and affordable medicines. Its operations encompass the manufacturing, import, and sale of pharmaceutical and allied consumer products, driven by a commitment to innovative healthcare solutions. The company maintains a robust Research & Development function, dedicated to discovering new treatments and disease prevention. Highnoon's product offerings include specialized medications, such as Feripro Capsule for Thalassemia. Recognized for its ethical marketing, strategic alliances, and strong performance, Highnoon aims to enhance accessibility to its products for patients and the medical community. The company also integrates environmental sustainability and social responsibility into its operations.

Recent filings

Filing Released Lang Actions
Credit of Final Cash Dividend
Notice of Dividend Amount Classification · 94% confidence The document is a formal letter to the stock exchange notifying the credit of the final cash dividend (Rs. 50 per share for year ended December 31, 2025) into shareholders’ bank accounts on May 15, 2026. It provides dividend amount and payment detail, which fits the “Notice of Dividend Amount” category.
2026-05-15 English
Video Recording of Corporate Briefing Session Highnoon Laboratories Limited
Report Publication Announcement Classification · 80% confidence The document is a brief notice to the stock exchange announcing that a Corporate Briefing Session video recording has been published online, with a link provided. It does not contain substantive financial data or presentation slides itself but simply announces the availability of the recording. Under the “Menu vs Meal” rule, this is an announcement of a publication rather than the report itself. Therefore, it best fits the Report Publication Announcement category (RPA).
2026-05-05 English
Revised Presentation of Corporate Briefing Session
Investor Presentation Classification · 87% confidence The document is structured as a slide deck titled “Corporate Briefing Session 2025” with agenda items, graphics, and summary tables covering company overview, macroeconomic outlook, industry dynamics, financial highlights, strategic direction, and ESG. It does not contain full financial statements or regulatory disclosures, nor is it a simple announcement of a report. This format and content align with an Investor Presentation.
2026-05-04 English
Certified Copies of Resolutions passed at the 43rd Annual General Meeting of Highnoon Laboratories Limited held on 30th April 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 80% confidence The document provides “certified true copies of resolutions passed” at the company’s 43rd Annual General Meeting (held on April 30, 2026), confirming which shareholder resolutions were approved (e.g., adoption of the annual financial statements, final dividend payment, auditors’ re-appointment, related-party transactions). This is not pre-meeting proxy materials or an annual report itself but the formal post-meeting resolution results. Therefore it falls under “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-04-30 English
Transmission of Quarterly Report for the Period Ended 31.03.2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Un-audited Financial Statements For the 1st Quarter Ended 31 March 2026' and contains detailed financial statements including condensed interim consolidated and unconsolidated financial statements, directors' report, financial highlights, earnings per share, and future outlook. The presence of quarterly financial data and analysis, including profit and loss, cash flows, and comprehensive income statements, indicates this is a comprehensive interim financial report for a period shorter than a full fiscal year. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-30 English
Corporate Briefing Session -Highnoon Laboratories Limited
Annual Report Classification · 95% confidence The document is titled 'Corporate Briefing Session 2025' and contains detailed sections on company overview, macroeconomic challenges, industry dynamics, financial analysis, stock market presence, strategic directions, and future outlook. It includes comprehensive financial data such as net revenue, EPS, profit after tax, assets, equity, dividend, and market capitalization for FY 2025. The document also references 'Annual Report 2025' multiple times, indicating it is a full annual report covering company activity and financial performance for the fiscal year 2025. The length of the document (15,000 characters) and the depth of financial and strategic information confirm it is not a brief announcement or presentation but a full report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.